Last Updated : May 1, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Zejula | Niraparib | Ovarian Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Zelboraf | Vemurafenib | Metastatic Melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Zeldox | Ziprasidone hydrochloride | Schizophrenia and related psychotic disorders | List with clinical criteria and/or conditions | Complete | ||
| Zemaira | Alpha1-proteinase inhibitor (Human) | Severe Alpha1-proteinase inhibitor deficiency | Reimburse with clinical criteria and/or conditions | Complete | ||
| Zenhale | Mometasone/formoterol | Asthma | List with clinical criteria and/or conditions | Complete | ||
| Zenhale (inhalation aerosol) | Mometasone furoate and formoterol | Asthma | Do not list | Complete | ||
| Zepatier | Elbasvir/grazoprevir | Hepatitis C, chronic | Reimburse with clinical criteria and/or conditions | Complete | ||
| Zeposia | ozanimod | Ulcerative colitis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Zeposia | ozanimod | Multiple Sclerosis, relapsing - remitting | Do not reimburse | Complete | ||
| Zepzelca | lurbinectedin | metastatic small cell lung cancer (SCLC) | Do not reimburse | Complete |
Last Updated : May 1, 2024